Aspire Biopharma enters $100M ELOC with Arena, terminates prior ELOC

Aspire Biopharma Holdings, Inc.

Entered into $100M equity line of credit (ELOC) with Arena Business Solutions, effective Nov 11, 2025.
Prior $100M ELOC with Arena dated Feb 13, 2025 mutually terminated on same day.
Company may sell shares at 96% of VWAP; maximum advance amount varies by time of notice (up to $20M).
Issued transaction fee shares and paid $40,000 in fees (cash and shares) to Arena.
ELOC term is 36 months; subject to ownership limitation of 9.99% and Nasdaq exchange cap until shareholder approval.

item 1.01 item 1.02 item 2.03 item 3.02 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.